With more than 20 years of experience in the pharmaceutical industry, Mr. Doucette joined the company in 2018. Previously, he held senior international finance and commercial positions in Wyeth Pharmaceuticals, later acquired by Pfizer Inc. His most recent role was Regional Commercial Director SEE/Turkey/Greece/Israel for Pfizer’s Consumer Healthcare business unit. Mr. Doucette holds a degree in business administration from Vienna University of Economics and Business.
Learn more about Neovii world
NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine
The epitope-based vaccine will target the most vulnerable part of the viral spike protein. Rapperswil, Switzerland and Tel Aviv, Israel, 12th May 2020 – Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially […]
Neovii & Mundipharma Confirm In-licensing Agreement
Neovii & Mundipharma Confirm In-licensing Agreement for the Development and Promotion of Grafalon® in China and Japan for Solid Organ & Stem Cell Transplant Neovii and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October 2018. Grafalon® is currently approved for prevention of […]
Neovii Pharmaceuticals AG announces new CEO
Rapperswil, Switzerland, September 15, 2017 – Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Juergen Pohle, Chief Commercial Officer, as CEO and Managing Director of Neovii as of January 1, 2018. CEO since June 2014, Alexandre Sudarskis established Neovii Pharmaceuticals’ headquarters in Switzerland […]